PD-1 And PD-L1 Inhibitors Market to Record a CAGR of 19.31%, Increasing Prevalence of Cancer to Boost Market Growth - Technavio
NEW YORK, Sept. 23, 2022 /PRNewswire/ -- The "PD-1 And PD-L1 Inhibitors Market by Application (solid tumors and blood-related tumors) and Geography (North America, Europe, Asia, and Rest of World (ROW)) - Forecast and Analysis 2022-2026" report has been added to Technavio's offering. The potential growth difference for the PD-1 and PD-l1 inhibitors market size between 2021 and 2026 is USD 49.34 billion. To get the exact CAGR and the Y-O-Y growth rate, Request a FREE PDF Sample Report
Regional Analysis
North Americawill account for 51% of the market's growth during the forecast period. This growth is attributed to factors such as the increasing prevalence of various solid tumors and blood-related tumors in the region and the sales of approved therapeutics. However, market growth in this region will be slower than the growth of the market in other regions. The US and Canada are the key countries for the PD-1 and PD-L1 inhibitors market in North America.
Key Market Dynamics
Market Driver: The increasing prevalence of cancer is driving the growth of the market. Various novel therapies have been approved in recent years. There is a gap between the demand and supply of these therapies, which has led to a huge unmet need. This has given vendors an opportunity to conduct studies on drugs such as PD-1 and PD-L1 inhibitors. The increasing approvals of these inhibitors are expected to increase their demand, which will drive the growth of the global PD-1 and PD-L1 inhibitors market.
Market Challenge: The high cost of available PD-1 and PD-L1 inhibitors will challenge the PD-1 and PD-L1 inhibitors market during the forecast period. The cost of cancer treatment is high, mainly due to laboratory tests, hospitalization, and the administration of novel PD-1 and PD-L1 inhibitor therapeutics. The treatment cost of these therapeutics depends on the stage of cancer. The high cost is leading to a rise in the preference for alternative treatment options such as surgeries, which is hindering the growth of the focused market.
Technavio has identified key trends, drivers, and challenges in the PD-1 and PD-L1 inhibitors market, which will help vendors improve their strategies to stay ahead of their competitors. View our FREE PDF Sample Report
Market Segmentation
By application, the blood-related tumors segment will be the largest contributor to market growth during the forecast period. The growth of this segment is attributed to factors such as the strong prevalence of leukemia and various types of lymphomas globally.
View our FREE PDF sample reportfor additional insights into the contribution of all the segments and regional opportunities in the report.
Some Companies Mentioned
Akeso Inc.
Alphamab Oncology
Amgen Inc.
AstraZeneca Plc
BeiGene Ltd.
Bristol Myers Squibb Co.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
Eli Lilly and Co.
F. Hoffmann La Roche Ltd.
Gilead Sciences Inc.
GlaxoSmithKline Plc
Innovent Biologics Inc.
Jiangsu Hengrui Pharmaceuticals Co. Ltd.
Merck and Co. Inc.
Merck KGaA
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Sanofi
Shanghai Jhunsi Biosciences Ltd.
Want your report customized? Speak to an analyst and personalize your report according to your needs
Related Reports
Point of Care Diagnostics Market by Product, End-user, and Geography - Forecast and Analysis 2022-2026: The point of care diagnostics market share is expected to increase by USD 13.09 billion from 2021 to 2026.
Pharmacogenomics Market by End-user and Geography - Forecast and Analysis 2022-2026: The pharmacogenomics market share is expected to increase by USD 2.50 billion from 2021 to 2026.
PD-1 And PD-L1 Inhibitors Market Scope
Report Coverage
Details
Page number
120
Base year
2021
Forecast period
2022-2026
Growth momentum & CAGR
Accelerate at a CAGR of 19.31%
Market growth 2022-2026
USD 49.34 billion
Market structure
Fragmented
YoY growth (%)
18.6
Regional analysis
North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution
North America at 51%
Key consumer countries
US, Canada, Germany, UK, and France
Competitive landscape
Leading companies, competitive strategies, consumer engagement scope
Companies profiled
Akeso Inc., Alphamab Oncology, Amgen Inc., AstraZeneca Plc, BeiGene Ltd., Bristol Myers Squibb Co., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Innovent Biologics Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck and Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi, and Shanghai Jhunsi Biosciences Ltd.
Market Dynamics
Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period.
Customization purview
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
Exhibit 100: Eli Lilly and Co. - Product / Service
Exhibit 101: Eli Lilly and Co. - Key offerings
10.8 F. Hoffmann La Roche Ltd.
Exhibit 102: F. Hoffmann La Roche Ltd. - Overview
Exhibit 103: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 104: F. Hoffmann La Roche Ltd. - Key news
Exhibit 105: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 106: F. Hoffmann La Roche Ltd. - Segment focus
10.9 GlaxoSmithKline Plc
Exhibit 107: GlaxoSmithKline Plc - Overview
Exhibit 108: GlaxoSmithKline Plc - Business segments
Exhibit 109: GlaxoSmithKline Plc - Key news
Exhibit 110: GlaxoSmithKline Plc - Key offerings
Exhibit 111: GlaxoSmithKline Plc - Segment focus
10.10 Merck and Co. Inc.
Exhibit 112: Merck and Co. Inc. - Overview
Exhibit 113: Merck and Co. Inc. - Business segments
Exhibit 114: Merck and Co. Inc. - Key news
Exhibit 115: Merck and Co. Inc. - Key offerings
Exhibit 116: Merck and Co. Inc. - Segment focus
10.11 Merck KGaA
Exhibit 117: Merck KGaA - Overview
Exhibit 118: Merck KGaA - Business segments
Exhibit 119: Merck KGaA - Key news
Exhibit 120: Merck KGaA - Key offerings
Exhibit 121: Merck KGaA - Segment focus
10.12 Sanofi
Exhibit 122: Sanofi - Overview
Exhibit 123: Sanofi - Business segments
Exhibit 124: Sanofi - Key news
Exhibit 125: Sanofi - Key offerings
Exhibit 126: Sanofi - Segment focus
11 Appendix
11.1 Scope of the report
11.2 Inclusions and exclusions checklist
Exhibit 127: Inclusions checklist
Exhibit 128: Exclusions checklist
11.3 Currency conversion rates for US$
Exhibit 129: Currency conversion rates for US$
11.4 Research methodology
Exhibit 130: Research methodology
Exhibit 131: Validation techniques employed for market sizing
Exhibit 132: Information sources
11.5 List of abbreviations
Exhibit 133: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
The American College of Clinical Pharmacology® (ACCP) is pleased to announce its 2024 ACCP Annual Meeting (#2024ACCP) will be held September 8 ? 10, 2024. We encourage you to join us for this transformative educational and scientific event! ACCP...
Somavedic, a trailblazer in sleep and digital pollution-neutralizing frequency therapy technology, in collaboration with researchers from the Eye Clinic of Jan Evangelista Purkyn? University and Masaryk Hospital in Ústí nad Labem in the Czech...
The Patient-Centered Outcomes Research Institute (PCORI) today announced the approval of funding awards totaling more than $150 million to support new patient-centered comparative clinical effectiveness research (CER) studies, research to strengthen...
Health Canada is advising that the following product(s) may pose serious health risks. For more information, including product photos and what you should do, visit these online safety alerts:
? Unauthorized sexual enhancement products
Health Canada...
Every treatment prescribed by a doctor today was once a part of research in a clinical trial. Clinical research is thriving at Thompson Cancer Survival Center....
According to the second annual Workplace Violence Prevention Training Annual Report for health care ? which provides insight into the state of workplace violence prevention training in health care ? the majority of health care professionals surveyed...